Core Viewpoint - On February 3, 2025, Haikang's stock fell by 5.47% with a trading volume of 430 million yuan, indicating market volatility and investor sentiment concerns [1] Financing Summary - On February 3, Haikang had a financing buy-in amount of 14.89 million yuan and a financing repayment of 13.57 million yuan, resulting in a net financing buy of 1.32 million yuan [1] - As of February 3, the total financing and securities lending balance for Haikang was 75.17 million yuan, with a financing balance of 68.38 million yuan, accounting for 0.13% of the circulating market value, which is above the 80th percentile of the past year [1] - The securities lending aspect showed that 900 shares were repaid and 1,300 shares were sold on February 3, with a selling amount of 61,700 yuan, while the securities lending balance was 6.79 million yuan, below the 20th percentile of the past year [1] Business Performance - As of September 30, 2025, Haikang reported a total revenue of 3.3 billion yuan for the first nine months, representing a year-on-year growth of 19.95%, while the net profit attributable to shareholders decreased by 22.66% to 295 million yuan [2] - The company has cumulatively distributed dividends of 3.673 billion yuan since its A-share listing, with 687 million yuan distributed over the past three years [2] Shareholder Structure - As of September 30, 2025, Haikang had 12,900 shareholders, an increase of 12.87% from the previous period, with an average of 37,342 circulating shares per shareholder, a decrease of 11.40% [2] - The top ten circulating shareholders include notable funds such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited, with varying changes in their holdings [3]

Group 1 - The stock price of Haishike fell by 5.81% to 47.33 CNY per share, with a trading volume of 73.84 million CNY and a turnover rate of 0.31%, resulting in a total market capitalization of 53.006 billion CNY [1] - Haishike Pharmaceutical Group Co., Ltd. was established on August 26, 2005, and went public on January 17, 2012. The company specializes in the research, development, production, and sales of chemical pharmaceuticals [1] - The main revenue composition of Haishike includes: anesthetic products (39.81%), revenue from cooperative products (23.59%), other indications (17.02%), parenteral nutrition (10.32%), antiemetics for tumors (8.15%), and other (supplement) (0.86%) [1] Group 2 - Morgan Fund holds a significant position in Haishike, with the Morgan Healthcare Stock A Fund (001766) owning 538,800 shares, accounting for 6.04% of the fund's net value, making it the seventh-largest holding [2] - The Morgan Healthcare Stock A Fund has a current size of 453 million CNY and has experienced a loss of 2.77% this year, ranking 5253 out of 5562 in its category [2] - The fund manager, Ye Min, has been in charge for 3 years and 193 days, with the best fund return during this period being 48.26% and the worst being 2.38% [2]

Core Viewpoint - The stock price of Haishike has experienced a decline, with a current trading price of 50.70 yuan per share, reflecting a year-to-date drop of 1.21% and a 5-day drop of 5.62% [1] Financial Performance - For the period from January to September 2025, Haishike achieved an operating revenue of 3.3 billion yuan, representing a year-on-year growth of 19.95%. However, the net profit attributable to shareholders decreased by 22.66% to 295 million yuan [2] - Cumulatively, Haishike has distributed a total of 3.673 billion yuan in dividends since its A-share listing, with 687 million yuan distributed over the past three years [3] Shareholder Structure - As of September 30, 2025, the number of shareholders of Haishike increased by 12.87% to 12,900, with an average of 37,342 circulating shares per person, down by 11.40% [2] - The top ten circulating shareholders include notable funds such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited, with varying changes in their holdings [3] Market Activity - As of January 22, Haishike's stock saw a trading volume of 51.53 million yuan, with a turnover rate of 0.21% and a total market capitalization of 56.78 billion yuan [1] - The main capital flow indicated a net outflow of 6.3653 million yuan, with significant selling activity observed [1]

Group 1 - The core viewpoint of the news is that 海思科 has shown a mixed performance in stock price and financial results, with a notable increase in stock price recently but a decline in net profit year-on-year [1][2]. Group 2 - As of January 9, 海思科's stock price increased by 2.09% to 56.15 CNY per share, with a total market capitalization of 628.83 billion CNY [1]. - The company has seen a year-to-date stock price increase of 9.41%, with a 9.41% rise over the last five trading days, a 3.98% decline over the last 20 days, and an 8.13% increase over the last 60 days [1]. - For the period from January to September 2025, 海思科 reported a revenue of 3.3 billion CNY, representing a year-on-year growth of 19.95%, while the net profit attributable to shareholders decreased by 22.66% to 295 million CNY [2]. - The company has distributed a total of 3.673 billion CNY in dividends since its A-share listing, with 687 million CNY distributed in the last three years [3]. - As of September 30, 2025, the number of shareholders increased by 12.87% to 12,900, while the average circulating shares per person decreased by 11.40% to 37,342 shares [2][3].

Group 1 - The core viewpoint of the news is that 海思科 (Haisco) has shown a slight increase in stock price, reaching 51.14 yuan per share, with a total market capitalization of 57.273 billion yuan as of December 31 [1] - 海思科's main business involves the research, development, production, and sales of chemical pharmaceuticals, with revenue composition as follows: anesthetic products 39.81%, cooperative product-related income 23.59%, other indications 17.02%, parenteral nutrition 10.32%, antiemetics for tumors 8.15%, and other (supplementary) 0.86% [1] Group 2 - 中欧医疗健康混合A (China Europe Medical Health Mixed A) fund has increased its holdings in 海思科 by 121,200 shares, bringing its total to 21,397,500 shares, which accounts for 4.44% of the circulating shares [2] - The fund has achieved a year-to-date return of 13.6% and a one-year return of 11.58%, ranking 5,297 out of 8,085 in its category [2] Group 3 - The fund manager of 中欧医疗健康混合A is 葛兰 (Gelan) and 赵磊 (Zhao Lei), with total fund assets of 435.44 billion yuan and 329.54 billion yuan respectively [3] - 葛兰 has a tenure of 10 years and 340 days, with the best fund return of 97.86% and the worst return of -35.13% during her tenure [3] Group 4 - 中欧医疗健康混合A has 海思科 as its tenth largest holding, representing 3.47% of the fund's net value, with a floating profit of approximately 11.1267 million yuan [4]

Core Viewpoint - The company, Haishike Pharmaceutical Group, has experienced fluctuations in stock performance and financing activities, indicating a mixed outlook for its financial health and investor sentiment [1][2]. Group 1: Stock Performance and Financing - On December 29, Haishike's stock fell by 2.16%, with a trading volume of 179 million yuan [1] - The financing data for December 29 shows a total financing buy of 9.025 million yuan and a net financing buy of 2.0689 million yuan, with a total financing balance of 53.2735 million yuan [1] - The current financing balance of 45.3621 million yuan represents 0.08% of the circulating market value, which is below the 20th percentile level over the past year, indicating a low financing position [1] Group 2: Company Financials - For the period from January to September 2025, Haishike reported a revenue of 3.3 billion yuan, reflecting a year-on-year growth of 19.95%, while the net profit attributable to shareholders decreased by 22.66% to 295 million yuan [2] - The company has distributed a total of 3.673 billion yuan in dividends since its A-share listing, with 687 million yuan distributed over the past three years [2] Group 3: Shareholder Structure - As of September 30, 2025, the number of shareholders increased by 12.87% to 12,900, with an average of 37,342 circulating shares per person, a decrease of 11.40% [2] - Among the top ten circulating shareholders, notable increases in holdings were observed for several funds, including China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited [3]

Core Viewpoint - The stock of Haishike Pharmaceutical Group has shown a significant increase of 59.34% year-to-date, despite recent declines in the short term, indicating potential volatility in its stock performance [1][2]. Group 1: Stock Performance - As of December 19, Haishike's stock price rose by 2.04% to 52.55 CNY per share, with a total market capitalization of 58.852 billion CNY [1]. - The stock has experienced a decline of 3.93% over the last five trading days, 6.48% over the last 20 days, and 4.02% over the last 60 days [1]. - The net outflow of main funds was 431,600 CNY, with large purchases amounting to 1.5072 million CNY, accounting for 9.30% of total transactions, while sales reached 1.9389 million CNY, making up 11.96% [1]. Group 2: Financial Performance - For the period from January to September 2025, Haishike reported a revenue of 3.3 billion CNY, reflecting a year-on-year growth of 19.95%, while the net profit attributable to shareholders decreased by 22.66% to 295 million CNY [2]. - Cumulatively, the company has distributed 3.673 billion CNY in dividends since its A-share listing, with 687 million CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders increased by 12.87% to 12,900, with an average of 37,342 circulating shares per person, a decrease of 11.40% [2]. - The top ten circulating shareholders include various funds, with notable increases in holdings by Central European Medical Health Mixed A and Hong Kong Central Clearing Limited [3].

Core Insights - The stock price of Haisco fell by 2.02% on November 25, trading at 57.81 CNY per share with a market capitalization of 64.742 billion CNY [1] - Haisco's stock has increased by 75.29% year-to-date, with a 5-day increase of 5.70% and a 20-day increase of 11.77% [1] - The company reported a revenue of 3.3 billion CNY for the first nine months of 2025, a year-on-year increase of 19.95%, while net profit decreased by 22.66% to 295 million CNY [2] Financial Performance - Haisco's main business revenue composition includes: anesthetic products (39.81%), cooperative product-related income (23.59%), and other therapeutic areas [1] - Cumulative cash dividends since A-share listing amount to 3.673 billion CNY, with 687 million CNY distributed over the past three years [3] Shareholder Information - As of September 30, 2025, Haisco had 12,900 shareholders, an increase of 12.87% from the previous period [2] - The top ten circulating shareholders include various funds, with notable increases in holdings from several institutional investors [3]

Core Viewpoint - The stock of Haishike has shown significant performance with a year-to-date increase of 69.22%, despite a recent decline over the past 60 days [1][2]. Group 1: Stock Performance - As of November 19, Haishike's stock price reached 55.81 CNY per share, with a market capitalization of 62.503 billion CNY [1]. - The stock has experienced a 2.05% increase during the trading session on November 19, with a trading volume of 55.9157 million CNY [1]. - Over the last five trading days, the stock has risen by 2.78%, and over the last 20 days, it has increased by 7.33%, while it has decreased by 5.09% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Haishike reported a revenue of 3.3 billion CNY, reflecting a year-on-year growth of 19.95% [2]. - The net profit attributable to shareholders for the same period was 295 million CNY, which represents a year-on-year decrease of 22.66% [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Haishike increased to 12,900, marking a 12.87% rise from the previous period [2]. - The average number of circulating shares per shareholder decreased by 11.40% to 37,342 shares [2]. - The company has distributed a total of 3.673 billion CNY in dividends since its A-share listing, with 687 million CNY distributed over the last three years [3]. Group 4: Institutional Holdings - As of September 30, 2025, notable institutional shareholders include China Europe Medical Health Mixed A, holding 21.3975 million shares, and Hong Kong Central Clearing Limited, holding 18.0601 million shares, both showing increases in their holdings [3]. - Other significant institutional shareholders include ICBC Frontier Medical Stock A and Huatai-PineBridge Innovation Medical Mixed A, with varying changes in their shareholdings [3].

Core Viewpoint - The stock of Haishike has shown a significant increase of 64.01% year-to-date, despite a recent decline of 2.96% over the past five trading days, indicating volatility in its performance [1][2]. Financial Performance - For the period from January to September 2025, Haishike achieved a revenue of 3.3 billion yuan, representing a year-on-year growth of 19.95%. However, the net profit attributable to shareholders decreased by 22.66% to 295 million yuan [2]. - Cumulatively, Haishike has distributed 3.673 billion yuan in dividends since its A-share listing, with 687 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Haishike increased by 12.87% to 12,900, with an average of 37,342 circulating shares per shareholder, down by 11.40% [2]. - The top ten circulating shareholders include several institutional investors, with notable increases in holdings from entities such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited [3]. Stock Market Activity - On November 10, Haishike's stock price rose by 2.04% to 54.09 yuan per share, with a trading volume of 123 million yuan and a turnover rate of 0.48%. The total market capitalization reached 60.576 billion yuan [1]. - The net outflow of main funds was 237,700 yuan, while large orders showed a mixed trend with 9.09 million yuan in purchases and 10.61 million yuan in sales [1]. Business Overview - Haishike Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and sales of chemical pharmaceuticals, with its main revenue sources being anesthetic products (39.81%), cooperative product-related income (23.59%), and other therapeutic areas [1]. - The company is categorized under the pharmaceutical and biological industry, specifically in chemical pharmaceuticals and formulations, and is involved in various concept sectors including Helicobacter pylori, hypertension treatment, and innovative drugs [1].